Related references
Note: Only part of the references are listed.Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer
Samanta Salvi et al.
SEMINARS IN CANCER BIOLOGY (2020)
Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
Meng Xu et al.
CLINICAL BREAST CANCER (2020)
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann et al.
CLINICAL CANCER RESEARCH (2020)
Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer
Xiaoliang Chen et al.
PROSTATE (2020)
The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer
Xinyue Wang et al.
ENDOCRINE-RELATED CANCER (2020)
Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies
Kevin H. Kensler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Androgen receptor: A promising therapeutic target in breast cancer
Stella K. Vasiliou et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2019)
Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer
Ingeborg E. de Kruijff et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer
Aristomenis Anestis et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
Maiko Okano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Consideration of breast cancer subtype in targeting the androgen receptor
Clasina M. Venema et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Shristi Bhattarai et al.
CANCERS (2019)
Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumab
Tianwen Chen et al.
SCIENTIFIC REPORTS (2019)
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98
Kevin H. Kensler et al.
BREAST CANCER RESEARCH (2019)
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Giuseppe Bronte et al.
BMC CANCER (2018)
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Ricardo L. B. Costa et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Inhibition of the Wnt/beta-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer
Zhuangzhuang Zhang et al.
CANCER RESEARCH (2018)
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
L. Gerratana et al.
CANCER TREATMENT REVIEWS (2018)
An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer
Fang Yang et al.
CELL DEATH AND DIFFERENTIATION (2018)
The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death
Kai-Wen Hsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer
S. Prekovic et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings
Matteo Centonze et al.
TRANSLATIONAL ONCOLOGY (2018)
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Angela Santonja et al.
Oncotarget (2018)
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
Sara Bravaccini et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)
H Bonnefoi et al.
ANNALS OF ONCOLOGY (2018)
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Marcello Tucci et al.
ONCOTARGETS AND THERAPY (2018)
PROGNOSTIC SIGNIFICANCE OF ANDROGEN RECEPTOR EXPRESSION IN HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER
Betul Bolat Kucukzeybek et al.
POLISH JOURNAL OF PATHOLOGY (2018)
The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Ivana Bozovic-Spasojevic et al.
CLINICAL CANCER RESEARCH (2017)
Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms
J. Feng et al.
ONCOGENE (2017)
Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer
Namratha Vontela et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Michael A. Gordon et al.
MOLECULAR CANCER THERAPEUTICS (2017)
MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression
Jessica L. Christenson et al.
HORMONES & CANCER (2017)
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer A Review
Miho Kono et al.
JAMA ONCOLOGY (2017)
Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
Yuka Asano et al.
CANCERS (2017)
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
Chun-Yu Liu et al.
PLOS ONE (2017)
Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer
Rui Huang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer
Yan Shen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
The Role of the Androgen Receptor Signaling in Breast Malignancies
Panagiotis F. Christopoulos et al.
ANTICANCER RESEARCH (2017)
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
Debora Basile et al.
CANCER TREATMENT REVIEWS (2017)
Are We Ready to Use ESR1 Mutations in Clinical Practice?
Rinath Jeselsohn
BREAST CARE (2017)
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
Corey Speers et al.
NPJ BREAST CANCER (2017)
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Manish Kohli et al.
CLINICAL CANCER RESEARCH (2017)
Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer
Valerie N. Barton et al.
CANCER RESEARCH (2017)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy
Miho Kono et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
Mohammad A. Aleskandarany et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
Erik Hilborn et al.
BRITISH JOURNAL OF CANCER (2016)
Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer
Aiyu Zhu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
Francesco Caiazza et al.
ENDOCRINE-RELATED CANCER (2016)
Targeting Androgen/Estrogen Receptors Crosstalk in Cancer
Michalis V. Karamouzis et al.
TRENDS IN CANCER (2016)
A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers
Damoun Safarpour et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer
Jin Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort
Karin Elebro et al.
CLINICAL CANCER RESEARCH (2015)
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot et al.
LANCET ONCOLOGY (2015)
Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
Valerie N. Barton et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Targeting the Androgen Receptor in Breast Cancer
KeeMing Chia et al.
CURRENT ONCOLOGY REPORTS (2015)
Expression of androgen receptor splice variants in clinical breast cancers
Theresa E. Hickey et al.
ONCOTARGET (2015)
Androgen receptor: structure, role in prostate cancer and drug discovery
M. H. Eileen Tan et al.
ACTA PHARMACOLOGICA SINICA (2015)
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul J. Toren et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Complexities of androgen receptor signalling in breast cancer
Keely M. McNamara et al.
ENDOCRINE-RELATED CANCER (2014)
Autophagy as a modulator and target in prostate cancer
Jason M. Farrow et al.
NATURE REVIEWS UROLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer
Christopher C. Coss et al.
STEROIDS (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Dawn R. Cochrane et al.
BREAST CANCER RESEARCH (2014)
A simple and reproducible prognostic index in luminal ER-positive breast cancers
I. Castellano et al.
ANNALS OF ONCOLOGY (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers
Isabell Witzel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
Irene Baccelli et al.
NATURE BIOTECHNOLOGY (2013)
The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization
C. Wang et al.
CELL DEATH & DISEASE (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network
Nancy U. Lin et al.
CANCER (2012)
Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer
Terence W. Friedlander et al.
CANCER RESEARCH (2012)
Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity
Francini de Mattos Lima Lin et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
Kati K. Waltering et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Research Resource: Interplay between the Genomic and Transcriptional Networks of Androgen Receptor and Estrogen Receptor α in Luminal Breast Cancer Cells
Eleanor F. Need et al.
MOLECULAR ENDOCRINOLOGY (2012)
The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
T. E. Hickey et al.
MOLECULAR ENDOCRINOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
Y. Li et al.
ONCOGENE (2012)
Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer
Ali Naderi et al.
NEOPLASIA (2012)
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Min Ni et al.
CANCER CELL (2011)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Laura C. Collins et al.
MODERN PATHOLOGY (2011)
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers
Y. Wang et al.
ONCOGENE (2011)
A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer
Kee Ming Chia et al.
NEOPLASIA (2011)
Expression of androgen receptors in primary breast cancer
S. Park et al.
ANNALS OF ONCOLOGY (2010)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
Leo A. Niemeier et al.
MODERN PATHOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Androgens in human breast carcinoma
Takashi Suzuki et al.
MEDICAL MOLECULAR MORPHOLOGY (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
Donata Micello et al.
VIRCHOWS ARCHIV (2010)
Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival
Hideyuki Akaza et al.
CANCER (2009)
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Amelia A. Peters et al.
CANCER RESEARCH (2009)
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor
D Masiello et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
